Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus.

Literature DB >> 22113707

Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus.

Leon I Igel¹, Amanda G Powell, Caroline M Apovian, Louis J Aronne.

Abstract

Overweight and obesity are now recognized as leading causes of diseases such as type 2 diabetes, hypertension, hyperlipidemia, and ultimately, cardiovascular disease. Despite the serious consequences, roughly two thirds of Americans are presently classified as overweight, and about one third are classified as obese. Weight loss via lifestyle modification and pharmacotherapy can promote improvement in many of these obesity-related conditions. This review addresses recent advances in pharmacotherapy for the management of obesity and obesity-related co-morbidities, with a focus on the management of obesity specifically in individuals with type 2 diabetes. Emphasis is also placed on a proposed paradigm shift from the glucose-centric to the weight-centric management of type 2 diabetes mellitus.

Entities: Chemical Disease

Mesh：

Year: 2012 PMID： 22113707 DOI： 10.1007/s11883-011-0221-0

Source DB: PubMed Journal: Curr Atheroscler Rep ISSN： 1523-3804 Impact factor: 5.113

45 in total

1. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Authors: Frank L Greenway; Ken Fujioka; Raymond A Plodkowski; Sunder Mudaliar; Maria Guttadauria; Janelle Erickson; Dennis D Kim; Eduardo Dunayevich
Journal: Lancet Date: 2010-07-29 Impact factor: 79.321

2. Meta-analysis: pharmacologic treatment of obesity.

Authors: Zhaoping Li; Margaret Maglione; Wenli Tu; Walter Mojica; David Arterburn; Lisa R Shugarman; Lara Hilton; Marika Suttorp; Vanessa Solomon; Paul G Shekelle; Sally C Morton
Journal: Ann Intern Med Date: 2005-04-05 Impact factor: 25.391

3. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

Authors: Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron
Journal: Diabetes Care Date: 2005-05 Impact factor: 19.112

4. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

Authors: R E Ratner; R Dickey; M Fineman; D G Maggs; L Shen; S A Strobel; C Weyer; O G Kolterman
Journal: Diabet Med Date: 2004-11 Impact factor: 4.359

5. Orlistat in the long-term treatment of obesity in primary care settings.

Authors: J Hauptman; C Lucas; M N Boldrin; H Collins; K R Segal
Journal: Arch Fam Med Date: 2000-02

6. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

Authors: Priscilla A Hollander; Philip Levy; Mark S Fineman; David G Maggs; Larry Z Shen; Susan A Strobel; Christian Weyer; Orville G Kolterman
Journal: Diabetes Care Date: 2003-03 Impact factor: 19.112

7. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

Authors: Edward S Horton; Cheryl Silberman; Keith L Davis; Rachele Berria
Journal: Diabetes Care Date: 2010-05-11 Impact factor: 19.112

8. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.

Authors: J Koska; E Ortega; J C Bunt; A Gasser; J Impson; R L Hanson; J Forbes; B de Courten; J Krakoff
Journal: Diabetologia Date: 2008-12-23 Impact factor: 10.122

9. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

Authors: Louis Aronne; Ken Fujioka; Vanita Aroda; Kim Chen; Amy Halseth; Nicole C Kesty; Colleen Burns; Cameron W Lush; Christian Weyer
Journal: J Clin Endocrinol Metab Date: 2007-05-15 Impact factor: 5.958

Advances in medical therapy for weight loss and the weight-centric management of type 2 diabetes mellitus.

1. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

2. Meta-analysis: pharmacologic treatment of obesity.

3. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

4. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.

5. Orlistat in the long-term treatment of obesity in primary care settings.

6. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.

7. Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database.

8. The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study.

9. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study.

10. Enhanced weight loss with pramlintide/metreleptin: an integrated neurohormonal approach to obesity pharmacotherapy.

Review 1. Why Weight? An Analytic Review of Obesity Management, Diabetes Prevention, and Cardiovascular Risk Reduction.

Review 2. The role of microRNAs in the healing of diabetic ulcers.

Review 3. Systems analysis and the prediction and prevention of Type 2 diabetes mellitus.

Review 4. Metabolic vs. hedonic obesity: a conceptual distinction and its clinical implications.